Lobby Law Development: Just When You (Almost) Had The New Disclosure Rules Figured Out, Here Come The Constitutional Challenges!
Client Alert | 1 min read | 02.07.08
Yesterday the National Association of Manufacturers (NAM) filed suit under the First Amendment to enjoin enforcement of a key provision of the Honest Leadership & Open Government Act of 2007. The Act requires associations that engage in lobbying to disclose the names of member organizations that contribute more than $5,000 in a quarterly period to the association’s lobbying activities, if the member actively participates in the planning, supervision, or control of such activities.
The new law applies to any entity that accepts money from other organizations to fund lobbying practices, but compliance will be particularly onerous for large associations. The new requirement has left many scratching their heads about whether to disclose the identities of members whose combined dues and voluntary contributions exceed $5,000, especially where the organization relies upon members to help run its operations, including activities that arguably support lobbying efforts.
NAM’s lawsuit challenges the new provision for failing, among other things, to define the term "actively participates." Organizations bear the responsibility of identifying members for whom disclosure is required, and disagreement between associations and members is a near certainty.
NAM seeks to enjoin the implementation of the new provision against any organization until the courts determine its legality. Lobbying reports are due February 14, 2008, but filers are not required to make the Act’s new disclosures challenged by NAM until the April 21, 2008 reporting deadline. NAM has requested that the district court rule on its motion for a preliminary injunction by April 14. Absent a favorable ruling, the Secretary of the Senate and Clerk of the House are charged with reporting non-compliance to the United States Attorney for the District of Columbia. Violators risk civil and criminal penalties of up to $200,000 and/or five years imprisonment.
Insights
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage.
Client Alert | 6 min read | 09.14.26
Mental Health Parity Bulletin Restates Best Practices for Evaluating Compliance
Client Alert | 6 min read | 09.11.26
It’s LIVE: The Cyber Resilience Act Reporting Is Mandatory as of Today - 11 September 2026
Client Alert | 10 min read | 09.11.26
Mining, Indigenous Consultation Rights, and Investment Treaty Protection
